Retatrutide 20mg

Description

• • Mechanism of Action: Retatrutide activates receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This unique “triple-agonist” approach is intended to provide more pronounced effects on weight loss and blood sugar management compared to medications that target only one or two of these pathways (like Ozempic or Zepbound).
  • Clinical Trial Results: Phase 2 clinical trials have shown promising results, with participants in the highest-dose groups losing an average of up to 24% of their body weight over 48 weeks. It has also demonstrated significant improvements in HbA1c levels, liver fat content, and cardiovascular risk factors in individuals with type 2 diabetes and obesity.

• FDA Approval Status: Retatrutide is an experimental drug and is not yet approved by the U.S. Food and Drug Administration (FDA) for human use. The FDA has issued warnings to companies distributing unapproved “retatrutide peptide” sold online, emphasizing that the only safe way to access the legitimate investigational medicine is through Eli Lilly-sponsored clinical trials.